WO2008123231A1 - Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same - Google Patents
Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same Download PDFInfo
- Publication number
- WO2008123231A1 WO2008123231A1 PCT/JP2008/055534 JP2008055534W WO2008123231A1 WO 2008123231 A1 WO2008123231 A1 WO 2008123231A1 JP 2008055534 W JP2008055534 W JP 2008055534W WO 2008123231 A1 WO2008123231 A1 WO 2008123231A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotide
- staple
- decoy
- stem structure
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
Abstract
Disclosed is a novel oligonucleotide which is highly capable of binding to NF-κB compared to a conventional oligonucleotide decoy for NF-κB, and is therefore useful as a NF-κB decoy. Also disclosed is use of the oligonucleotide for medical purposes. The oligonucleotide is a cyclic staple-type oligodeoxynucleotide composed of a stem structure and two loop structures attached to both termini of the stem structure, wherein the stem structure comprises a double-strand composed of two chains, and each of the two chains comprises a consensus sequence and a 5'-addition sequence and a 3'-addition sequence each having a specific nucleotide sequence and attached to both termini of the consensus sequence. The cyclic staple-type oligodeoxynucleotide is useful as a prophylactic, ameliorating or therapeutic agent for an ischemic disease, an allergic disease, an inflammatory disease, an autoimmune disease, metastasis/invasion of cancer, or cachexia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007-078316 | 2007-03-26 | ||
JP2007078316A JP2010130900A (en) | 2007-03-26 | 2007-03-26 | NOVEL CYCLIC STAPLE-TYPE OLIGONUCLEOTIDE, AND NF-kappaB DECOY COMPRISING THE SAME |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008123231A1 true WO2008123231A1 (en) | 2008-10-16 |
Family
ID=39830724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/055534 WO2008123231A1 (en) | 2007-03-26 | 2008-03-25 | Novel cyclic staple-type oligonucleotide, and nf-κb decoy comprising the same |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2010130900A (en) |
WO (1) | WO2008123231A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026342A1 (en) * | 2002-09-20 | 2004-04-01 | Anges Mg, Inc. | AGENT CONTAINING NFκB DECOY FOR PROTECTING GRAFT AGAINST NEOINTIMAL THICKENING |
JP2005160464A (en) * | 2003-12-02 | 2005-06-23 | Corgentech Inc | NF-kappaB OLIGONUCLEOTIDE DECOY MOLECULE |
WO2007072909A1 (en) * | 2005-12-22 | 2007-06-28 | Anges Mg, Inc. | NOVEL OLIGONUCLEOTIDE AND NF-κB DECOY COMPRISING THE SAME |
-
2007
- 2007-03-26 JP JP2007078316A patent/JP2010130900A/en not_active Withdrawn
-
2008
- 2008-03-25 WO PCT/JP2008/055534 patent/WO2008123231A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026342A1 (en) * | 2002-09-20 | 2004-04-01 | Anges Mg, Inc. | AGENT CONTAINING NFκB DECOY FOR PROTECTING GRAFT AGAINST NEOINTIMAL THICKENING |
JP2005160464A (en) * | 2003-12-02 | 2005-06-23 | Corgentech Inc | NF-kappaB OLIGONUCLEOTIDE DECOY MOLECULE |
WO2007072909A1 (en) * | 2005-12-22 | 2007-06-28 | Anges Mg, Inc. | NOVEL OLIGONUCLEOTIDE AND NF-κB DECOY COMPRISING THE SAME |
Non-Patent Citations (3)
Title |
---|
AHN J.D. ET AL.: "Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia", GENE THER., vol. 9, no. 24, 2002, pages 1682 - 1692, XP002314528 * |
HOSOYA T. ET AL.: "Sequence-specific inhibition of a transcription factor by circular dumbbell DNA oligonucleotides", FEBS LETT., vol. 461, no. 3, 1999, pages 136 - 140, XP004260536 * |
KUNUGIZA Y. ET AL.: "Inhibitory effect of ribbon-type NF-kappaB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro and in vivo", ARTHRITIS RES. THER., vol. 8, no. 4, 2006, pages R103, XP021020579 * |
Also Published As
Publication number | Publication date |
---|---|
JP2010130900A (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012031515A3 (en) | Low-modification biocompatible high polymer sulfhydryl-modified derivatives, cross-linked material thereof, and uses of said material | |
WO2006124880A3 (en) | Systems and methods to facilitate endoscopic interventions | |
WO2007127263A3 (en) | Therapeutic uses of urolithins | |
WO2007013059A3 (en) | Extending intrabody capsule | |
WO2008033432A3 (en) | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides | |
EP2567964A3 (en) | Monomer Compositions for the Synthesis of RNA, Methods of Synthesis, and Methods of Deprotection | |
WO2009011882A3 (en) | Endoscopic implant system and method | |
EP1613251A4 (en) | Devices, systems, and methods to fixate tissue within the regions of body, such as the pharyngeal conduit | |
EP1691760A4 (en) | Devices systems, and methods to fixate tissue within the regions of the body, such as the pharyngeal conduit | |
WO2007121131A3 (en) | Medical devices including shape memory materials | |
IL200407A (en) | Stable digestive enzyme compositions, methods of producing the same and uses thereof | |
HK1124336A1 (en) | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties | |
WO2007056384A3 (en) | Mesh anchoring system | |
WO2006127883A3 (en) | Personal care compositions comprising saccharide-siloxane copolymers | |
WO2007007173A3 (en) | Human anti-madcam antibodies | |
ZA200708327B (en) | Reduction of postoperative pain medication | |
WO2006081517A3 (en) | Embolization using poly-4-hydroxybutyrate particles | |
EP1929043A4 (en) | Genemap of the human genes associated with crohn's disease | |
EP1883708A4 (en) | Genemap of the human genes associated with crohn's disease | |
EP2097540A4 (en) | Genemap of the human genes associated with crohn's disease | |
EP1771188A4 (en) | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia | |
WO2008016677A3 (en) | Preparation and utility of deuterated amphetamines | |
WO2014022566A3 (en) | Synthesis of deuterated ribo nucleosides, n-protected phosphoramidites, and oligonucleotides | |
WO2007075923A3 (en) | Treatment of synucleinopathies | |
ZA200711116B (en) | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08738829 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08738829 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |